Harbor Capital Advisors Inc. Grows Stock Holdings in Intellia Therapeutics, Inc. (NASDAQ:NTLA)

Harbor Capital Advisors Inc. grew its holdings in Intellia Therapeutics, Inc. (NASDAQ:NTLA - Free Report) by 71.0% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 79,205 shares of the company's stock after purchasing an additional 32,893 shares during the quarter. Harbor Capital Advisors Inc. owned approximately 0.08% of Intellia Therapeutics worth $1,628,000 at the end of the most recent quarter.

A number of other large investors also recently bought and sold shares of NTLA. First Horizon Advisors Inc. raised its position in shares of Intellia Therapeutics by 22.1% during the 2nd quarter. First Horizon Advisors Inc. now owns 2,604 shares of the company's stock worth $58,000 after buying an additional 472 shares in the last quarter. Elmwood Wealth Management Inc. raised its position in shares of Intellia Therapeutics by 0.9% in the 3rd quarter. Elmwood Wealth Management Inc. now owns 67,774 shares of the company's stock valued at $1,393,000 after acquiring an additional 600 shares during the period. Interchange Capital Partners LLC grew its stake in shares of Intellia Therapeutics by 6.5% during the 1st quarter. Interchange Capital Partners LLC now owns 10,909 shares of the company's stock worth $303,000 after acquiring an additional 670 shares in the last quarter. Allspring Global Investments Holdings LLC lifted its holdings in Intellia Therapeutics by 9.2% during the 1st quarter. Allspring Global Investments Holdings LLC now owns 8,894 shares of the company's stock valued at $245,000 after purchasing an additional 750 shares during the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. increased its position in shares of Intellia Therapeutics by 27.6% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,674 shares of the company's stock worth $77,000 after purchasing an additional 794 shares during the period. Hedge funds and other institutional investors own 88.77% of the company's stock.

Insider Buying and Selling at Intellia Therapeutics

In other news, CAO Michael P. Dube sold 2,012 shares of Intellia Therapeutics stock in a transaction on Wednesday, October 2nd. The stock was sold at an average price of $19.01, for a total value of $38,248.12. Following the completion of the transaction, the chief accounting officer now directly owns 47,012 shares in the company, valued at approximately $893,698.12. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 3.20% of the company's stock.

Intellia Therapeutics Stock Up 4.1 %

Shares of NTLA stock traded up $0.63 during mid-day trading on Wednesday, reaching $16.06. 3,445,453 shares of the company were exchanged, compared to its average volume of 1,648,814. The business's 50 day simple moving average is $19.55 and its 200 day simple moving average is $22.34. Intellia Therapeutics, Inc. has a fifty-two week low of $13.95 and a fifty-two week high of $34.87.

Intellia Therapeutics (NASDAQ:NTLA - Get Free Report) last issued its quarterly earnings results on Thursday, August 8th. The company reported ($1.52) EPS for the quarter, missing analysts' consensus estimates of ($1.23) by ($0.29). The firm had revenue of $7.00 million during the quarter, compared to the consensus estimate of $19.68 million. During the same period in the previous year, the business posted ($1.40) EPS. The firm's revenue was down 48.5% on a year-over-year basis. On average, equities research analysts predict that Intellia Therapeutics, Inc. will post -5.21 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

NTLA has been the topic of a number of recent research reports. Chardan Capital cut their target price on Intellia Therapeutics from $94.00 to $88.00 and set a "buy" rating on the stock in a report on Thursday, October 24th. Royal Bank of Canada reaffirmed an "outperform" rating and issued a $54.00 price target on shares of Intellia Therapeutics in a research note on Thursday, September 19th. The Goldman Sachs Group dropped their target price on Intellia Therapeutics from $31.00 to $20.00 and set a "neutral" rating on the stock in a report on Friday, October 25th. Citigroup reduced their price objective on Intellia Therapeutics from $25.00 to $19.00 and set a "neutral" rating for the company in a research report on Friday, October 25th. Finally, Evercore ISI raised Intellia Therapeutics to a "strong-buy" rating in a research note on Friday, August 9th. One investment analyst has rated the stock with a sell rating, five have given a hold rating, eleven have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, Intellia Therapeutics has a consensus rating of "Moderate Buy" and an average target price of $59.13.

Intellia Therapeutics Profile

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.